Ocular compositions

The present invention relates to ocular compositions for the controlled release of a therapeutic agent. The ocular composition comprises at least 20% w/w of a therapeutic agent; 5 to 75% w/w of a photopolymerizable composition selected from the group consisting of fragments or monomers of polyalkyle...

Full description

Saved in:
Bibliographic Details
Main Authors JONES, David, THAKUR, Raghu Raj Singh, SONAWANE, Rahul, WANG, Yujing, SOLIMAN, Karim
Format Patent
LanguageEnglish
Published 12.08.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to ocular compositions for the controlled release of a therapeutic agent. The ocular composition comprises at least 20% w/w of a therapeutic agent; 5 to 75% w/w of a photopolymerizable composition selected from the group consisting of fragments or monomers of polyalkylene glycol mono-acrylate, polyalkylene glycol diacrylate, polyalkylene glycol methacrylate and polyalkylene glycol dimethacrylate, and mixtures, copolymers, and block copolymers thereof.; 0.1 to 40% w/w of a biodegradable polymer selected from the group consisting of lactide/glycolide copolymer (including poly(lactide-co-glycolide) (PLGA)), poly (L-lactide) (PLA), polyhydroxyalkanoates, including polyhydroxybutyrate, polyglycolic acid (PGA), polycaprolactone (PCL), poly (DL-lactide) (PDL), poly (D-lactide), lactide/caprolactone copolymer, poly-L-lactide-co-caprolactone (PLC) and mixtures, copolymers, and block copolymers thereof; and a photoinitiator.
Bibliography:Application Number: AU20190408549